DiaSorin (OTCMKTS:DSRLF) Shares Gap Down – What’s Next?

DiaSorin S.p.A. (OTCMKTS:DSRLF) shares gapped down before the market opened on Thursday . The stock had previously closed at $78.45, but opened at $74.25. DiaSorin shares last traded at $74.25, with a volume of 10 shares traded.

Wall Street Analysts Forecast Growth

DSRLF has been the topic of a number of research reports. UBS Group lowered DiaSorin from a “buy” rating to a “neutral” rating in a report on Thursday, April 9th. Deutsche Bank Aktiengesellschaft downgraded DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday. Zacks Research upgraded DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. Finally, Piper Sandler initiated coverage on shares of DiaSorin in a report on Thursday, June 11th. They issued a “neutral” rating on the stock. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold”.

DiaSorin Trading Down 11.7%

The business has a 50-day simple moving average of $72.26 and a 200-day simple moving average of $75.52.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.